See more : High Arctic Energy Services Inc (HGHAF) Income Statement Analysis – Financial Results
Complete financial analysis of Reunion Neuroscience Inc. (REUN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reunion Neuroscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- On Holding AG (ONON) Income Statement Analysis – Financial Results
- Aeon Hokkaido Corporation (7512.T) Income Statement Analysis – Financial Results
- Celadon Pharmaceuticals Plc (CEL.L) Income Statement Analysis – Financial Results
- Schweitzer-Mauduit International, Inc. (SWM) Income Statement Analysis – Financial Results
- Fairfax Financial Holdings Limited (FRFFF) Income Statement Analysis – Financial Results
Reunion Neuroscience Inc. (REUN)
About Reunion Neuroscience Inc.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 0.00 | 4.86M | 960.90K | 1.00K |
Cost of Revenue | 0.00 | 9.15M | 1.54M | 9.40K |
Gross Profit | 0.00 | -4.29M | -583.43K | -8.40K |
Gross Profit Ratio | 0.00% | -88.27% | -60.72% | -840.30% |
Research & Development | 12.98M | 7.31M | 3.42M | 193.19K |
General & Administrative | 12.96M | 34.48M | 12.06M | 2.63M |
Selling & Marketing | 0.00 | 3.23M | 1.63M | 305.71K |
SG&A | 12.96M | 37.72M | 13.69M | 2.93M |
Other Expenses | 2.02M | 3.71M | 1.34M | 139.98K |
Operating Expenses | 27.96M | 48.74M | 18.45M | 3.27M |
Cost & Expenses | 27.96M | 57.89M | 19.99M | 3.28M |
Interest Income | 691.79K | 425.90K | 51.04K | 2.66K |
Interest Expense | 17.73M | 1.10M | 303.30K | 22.56K |
Depreciation & Amortization | 3.23M | 3.60M | 1.39M | 146.32K |
EBITDA | -17.15M | -49.00M | -17.58M | -3.13M |
EBITDA Ratio | 0.00% | -1,008.13% | -1,829.88% | -312,585.70% |
Operating Income | -20.37M | -52.60M | -18.98M | -3.27M |
Operating Income Ratio | 0.00% | -1,082.27% | -1,974.99% | -327,217.70% |
Total Other Income/Expenses | -17.73M | 14.50M | -4.14M | 643.85K |
Income Before Tax | -38.10M | -54.69M | -23.12M | -2.63M |
Income Before Tax Ratio | 0.00% | -1,125.30% | -2,405.84% | -262,832.40% |
Income Tax Expense | 28.12M | 1.10M | 303.30K | 22.56K |
Net Income | -66.22M | -55.79M | -23.42M | -2.65M |
Net Income Ratio | 0.00% | -1,147.86% | -2,437.41% | -265,088.60% |
EPS | -5.69 | -4.83 | -3.54 | -0.35 |
EPS Diluted | -5.69 | -4.83 | -3.54 | -0.35 |
Weighted Avg Shares Out | 11.64M | 11.55M | 6.61M | 7.60M |
Weighted Avg Shares Out (Dil) | 11.64M | 11.55M | 6.61M | 7.60M |
Field Trip Health Ltd. to Participate in H.C.
3 Psychedelic Stocks to Play the Shroom Boom
9 Psychedelic Stocks to Watch For 2022
Field Trip Health Ltd. to Participate in Upcoming Conferences in December 2021
3 Psychedelic Stocks for Potential Out-of-This-World Gains
Field Trip Health Ltd.'s (FTRP) CEO Joseph del Moral on Q2 2022 Results - Earnings Call Transcript
Field Trip Health Ltd. to Participate in Upcoming Conferences in November 2021
Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET
Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton
Field Trip Health Ltd. To Present At The KCSA Psychedelics Virtual Investor Conference On October 13th
Source: https://incomestatements.info
Category: Stock Reports